Summary of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Ratings

May 17, 2018 - By Julie Barnes

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Corporate Logo

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Ratings Coverage

In total 2 analysts cover Collegium Pharmaceutical (NASDAQ:COLL). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 6 are the (NASDAQ:COLL)’s analyst reports since November 29, 2017 according to StockzIntelligence Inc. On Thursday, December 14 Piper Jaffray maintained Collegium Pharmaceutical, Inc. (NASDAQ:COLL) rating. Piper Jaffray has “Buy” rating and $23.0 target. On Monday, February 12 the firm earned “Buy” rating by Piper Jaffray. The company rating was maintained by Piper Jaffray on Wednesday, November 29. In Tuesday, January 23 report Piper Jaffray maintained the stock with “Buy” rating. On Sunday, February 11 the firm earned “Buy” rating by Jefferies. On Thursday, December 7 the stock of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has “Buy” rating given by Piper Jaffray. Listed here are Collegium Pharmaceutical, Inc. (NASDAQ:COLL) PTs and latest ratings.

12/02/2018 Broker: Piper Jaffray Rating: Buy New Target: $33.0 Maintain
11/02/2018 Broker: Jefferies Rating: Buy New Target: $32.0 Maintain
23/01/2018 Broker: Piper Jaffray Rating: Buy New Target: $33.0 Maintain
14/12/2017 Broker: Piper Jaffray Rating: Buy New Target: $23.0 Maintain
07/12/2017 Broker: Piper Jaffray Rating: Buy New Target: $24.0 Maintain
29/11/2017 Broker: Piper Jaffray Rating: Buy New Target: $19.0 Maintain

Ticker’s shares touched $25.1 during the last trading session after 2.20% change.Currently Collegium Pharmaceutical, Inc. is uptrending after 133.98% change in last May 17, 2017. COLL has 186,789 shares volume. The stock outperformed the S&P500 by 122.43%.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases.The firm is worth $829.40 million. It offers Xtampza, an oral formulation of oxycodone, for the management of pain.Currently it has negative earnings. The firm also develops Onsolis, a transmucosal immediate-release fentanyl film indicated for the management of breakthrough pain in cancer patients 18 years of age and older.

For more Collegium Pharmaceutical, Inc. (NASDAQ:COLL) news posted briefly go to: Nasdaq.com, Benzinga.com, Seekingalpha.com, Globenewswire.com or Globenewswire.com. The titles are as follows: “Why Depomed Inc.’s Shares Soared 23.2% Higher” posted on May 10, 2018, “Benzinga’s Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway” on May 09, 2018, “FDA OKs first non-opioid treatment for opioid withdrawal” with a publish date: May 16, 2018, “Collegium Reports First Quarter Financial Results and Provides Corporate Update” and the last “Collegium to Present at the Deutsche Bank Health Care Conference” with publication date: May 02, 2018.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.